AR059233A1 - Mimotopos de polisacaridos capsulares de neisseria meningitidis y formulaciones farmaceuticas - Google Patents
Mimotopos de polisacaridos capsulares de neisseria meningitidis y formulaciones farmaceuticasInfo
- Publication number
- AR059233A1 AR059233A1 ARP070100376A ARP070100376A AR059233A1 AR 059233 A1 AR059233 A1 AR 059233A1 AR P070100376 A ARP070100376 A AR P070100376A AR P070100376 A ARP070100376 A AR P070100376A AR 059233 A1 AR059233 A1 AR 059233A1
- Authority
- AR
- Argentina
- Prior art keywords
- peptides
- formulations
- meningitidis
- nmgacps
- serogroups
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 5
- 238000009472 formulation Methods 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 229960005486 vaccine Drugs 0.000 abstract 3
- 241000588650 Neisseria meningitidis Species 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 150000004676 glycans Chemical class 0.000 abstract 2
- 229920001282 polysaccharide Polymers 0.000 abstract 2
- 239000005017 polysaccharide Substances 0.000 abstract 2
- 230000001681 protective effect Effects 0.000 abstract 2
- 241000894006 Bacteria Species 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 241000588653 Neisseria Species 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000005847 immunogenicity Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 244000005700 microbiome Species 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000004044 response Effects 0.000 abstract 1
- 238000001228 spectrum Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente está relacionada con la obtencion de péptidos antigénicos vacunales para la prevencion o terapéutica de enfermedades bacterianas, virales, cancerosas, o de otro origen. Desarrollo de formulaciones capaces de elevar el espectro protector de vacunas ya existentes y extenderlo contra diferentes patogenos. Para lograr este objetivo se aislaron e identificaron péptidos miméticos moleculares de polisacáridos capsulares de los serogrupos A y C de Neisseria meningitidis, a partir de una coleccion de péptidos de 15 aminoácidos dispuestos al azar empleando sueros humanos con altos niveles de anticuerpos dirigidos contra los polisacáridos capsulares de los serogrupos A y C del meningococo. La inmunogenicidad de los péptidos se evaluo en biomodelos animales, demostrando su valor como antígenos inductores de respuesta inmune con actividad bactericida contra N. meningitidis. Las formulaciones resultantes de la presente son aplicables en la industria farmacéutica como formulaciones vacunales para uso humano. Reivindicacion 1: Péptidos denominados NMGACPS 1 -12, caracterizados por ser antígenos capaces de generar en el organismo receptor una respuesta protectora contra infecciones causadas por bacterias del género Neisseria y tener las secuencias de aminoácidos identificadas en el listado de secuencias como Seq ID 13-24. Reivindicacion 10: Microorganismos genéticamente modificados caracterizados porque contienen los fragmentos de ADN nombrados ADN-NMGACPS 1-12, caracterizados por tener las secuencias de base identificadas en el listado de secuencias como Seq ID 1-12, o segmentos de estos, solos o formando parte de otra secuencia génica.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20060020 | 2006-01-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR059233A1 true AR059233A1 (es) | 2008-03-19 |
Family
ID=38327738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070100376A AR059233A1 (es) | 2006-01-31 | 2007-01-30 | Mimotopos de polisacaridos capsulares de neisseria meningitidis y formulaciones farmaceuticas |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR059233A1 (es) |
| WO (1) | WO2007087758A2 (es) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1270939B (it) * | 1993-05-11 | 1997-05-26 | Angeletti P Ist Richerche Bio | Procedimento per la preparazione di immunogeni e reagenti diagnostici,e immunogeni e reagenti diagnostici cosi' ottenibili. |
| JP2002542264A (ja) * | 1999-04-21 | 2002-12-10 | パウダージェクト ヴァクシンズ，インコーポレイテッド | 核酸による免疫化 |
-
2007
- 2007-01-29 WO PCT/CU2007/000001 patent/WO2007087758A2/es not_active Ceased
- 2007-01-30 AR ARP070100376A patent/AR059233A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007087758A3 (es) | 2007-11-15 |
| WO2007087758A2 (es) | 2007-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Weinberger et al. | Vaccines for the elderly | |
| JP6874031B2 (ja) | アイメリアに対する免疫応答を強化するか又はアイメリア感染症を制限する組成物及び方法 | |
| Mirzaei et al. | The study of H. pylori putative candidate factors for single-and multi-component vaccine development | |
| EP2525817B1 (en) | Vaccine vectors and methods of enhancing immune responses | |
| Zhang et al. | Single-walled carbon nanotubes as delivery vehicles enhance the immunoprotective effect of a DNA vaccine against spring viremia of carp virus in common carp | |
| CN113454102A (zh) | 非洲猪瘟疫苗 | |
| CN102037135A (zh) | 增强对有鞭毛的细菌的免疫反应的组合物和方法 | |
| Ellis | Technologies for the design, discovery, formulation and administration of vaccines | |
| Mansour et al. | An improved tobacco mosaic virus (TMV)-conjugated multiantigen subunit vaccine against respiratory tularemia | |
| KR101919002B1 (ko) | 구제역 바이러스의 가용성 다가 항원단백질 및 이의 용도 | |
| Simerska et al. | Oral vaccine delivery-new strategies and technologies | |
| Rezaei et al. | In silico design and in vivo evaluation of two multi-epitope vaccines containing build-in adjuvant with chitosan nanoparticles against uropathogenic Escherichia coli | |
| JP2024156862A (ja) | 百日咳ブースターワクチン | |
| Gestal et al. | Immunomodulation as a novel strategy for prevention and treatment of Bordetella spp. infections | |
| ES2824402T3 (es) | Vacunas atenuadas contra Pasteurella multocida y procedimientos de fabricación y uso de las mismas | |
| Chen et al. | Biotechnologies applied in biomedical vaccines | |
| ES2337653T3 (es) | Vacuna contra patogenos microbianos. | |
| Wang et al. | Immunological and protective effects of Bordetella bronchiseptica subunit vaccines based on the recombinant N-terminal domain of dermonecrotic toxin | |
| Chavda et al. | History of vaccination | |
| AR059233A1 (es) | Mimotopos de polisacaridos capsulares de neisseria meningitidis y formulaciones farmaceuticas | |
| JP6401148B2 (ja) | 抗原および抗原の組み合わせ | |
| ES2375280T3 (es) | Vacuna para prevenir y tratar la rinitis atrófica progresiva porcina. | |
| Vordermeier et al. | Synthetic peptide vaccination in cattle: induction of strong cellular immune responses against peptides derived from the Mycobacterium bovis antigen Rv3019c | |
| Kahraman et al. | A novel trivalent inactivated Salmonella vaccine formulated with CpG ODNs to enhance the cellular immunity in chickens | |
| Greener | Next generation immunology: the quest for a universal vaccine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |